Rationale: Heme plays a critical role in gas exchange, mitochondrial energy production, and antioxidant defense in cardiovascular system. The mitochondrial transporter ATP-binding cassette (ABC) B10 has been suggested to export heme out of the mitochondria and is required for normal hemoglobinization of erythropoietic cells and protection against ischemia-reperfusion injury in the heart; however, its primary function has not been established.
H eme synthesis has been extensively studied in the context of red blood cell development and hemoglobinization, and the defects of this pathway often cause sideroblastic anemia and neurological deficits in humans. 1, 2 In addition to its role in gas exchange, heme is required for the function of many essential cardiac enzymes, including mitochondrial electron transport chain complexes and heme-containing antioxidant proteins, such as peroxidases and catalases. 3 Furthermore, supplementation of hypertensive rats with heme was shown to be protective against myocardial fibrosis and oxidative stress through induction of heme oxygenase 1 and activation of phosphatidylinositol 3-kinase/AKT signaling pathway. 4 Thus, heme is required for the maintenance of cardiovascular health both as a catalytic subunit of enzymes and as a signaling molecule.
Heme biosynthesis begins in the mitochondria with condensation of glycine and succinyl coenzyme A (CoA) to form δ-aminolevulinic acid (ALA) by the rate-limiting enzyme ALA synthase 1/2 (ALAS1/2), 5 whose levels are tightly regulated by cellular iron and heme. Next, ALA is exported out of the mitochondria through an as yet unidentified mechanism, and the subsequent 4 cytosolic reactions convert ALA into coproporphyrinogen III. Finally, coproporphyrinogen III is transported back into the mitochondria for the synthesis of protoporphyrin IX (PPIX), followed by insertion of iron by ferrochelatase to yield heme. 3, 6 Iron is imported into the mitochondria by mitoferrin 1 and 2 (Mfrn1/2). Mfrn1 is predominantly expressed in hematopoietic tissues, and its levels are significantly increased during the maturation of red blood cells. [7] [8] [9] On the contrary, Mfrn2 is ubiquitously expressed, not regulated during erythrocyte development, and is the primary isoform responsible for iron uptake into the mitochondria of nonhematopoietic cells. July 19, 2013 organisms from single-cell bacteria to humans. 10, 11 They use the energy of ATP hydrolysis to transport diverse substrates across cellular membranes. 11 Although >50 ABC proteins have been identified in the human genome, only 4 of them localize to the mitochondria, and their functions in the heart remain understudied. 12 ABCB6 is an outer membrane protein and has been suggested to import coproporphyrinogen III into the mitochondria for the synthesis of heme, 13, 14 although a controversy about its mitochondrial localization and role in heme synthesis exists. 15 ABCB7 regulates mitochondrial and cellular iron homeostasis and was shown to interact with ferrochelatase. 16 A mutation of this protein was found in patients with X-linked sideroblastic anemia with ataxia, suggesting that ABCB7 may participate in heme biosynthesis.
17 ABCB8 (also known as mABC1) was recently shown to protect against oxidative stress, 18 facilitate iron export out of the mitochondria, and play a role in the maturation of cytosolic iron-sulfur cluster proteins. 19 However, heme levels were not altered in the hearts of ABCB8 knockout mice, suggesting that this transporter may not be involved in the regulation of heme homeostasis. 19 Finally, several reports suggested that ABCB10 (also known as ABC-me and mABC2) plays a role in hemoglobinization of erythropoietic cells and could function to export heme out of the mitochondria, 6, 20, 21 although the biological substrate for this protein has not been identified yet.
ABCB10 is a mitochondrial inner membrane half-protein that homodimerizes to form a functional transporter. 22 Tissues with the highest levels of ABCB10 expression include hematopoietic lineages, heart, liver, and kidney, 20, 23 and ABCB10 was shown to be required for normal red blood cell development. 24 Overexpression of ABCB10 enhances hemoglobin synthesis during maturation of murine erythroleukemia (MEL) cells but does not initiate hemoglobin synthesis in undifferentiated cells. 20 ABCB10 interacts with and stabilizes Mfrn1, but not Mfrn2, in developing hematopoietic cells. This interaction is associated with enhanced iron uptake into the mitochondria. 25 Furthermore, ferrochelatase was found to transiently interact with ABCB10-Mfrn1 complex, 21 suggesting coupling of mitochondrial iron import and integration of iron into the PPIX ring for heme synthesis. Finally, ABCB10 knockout mice die in utero from severe anemia, 26 and ABCB10 heterozygous mice display impaired recovery from ischemia-reperfusion injury in the heart as a result of increased production of reactive oxygen species (ROS). 27 In this study, we show that ABCB10 plays a role in the early steps of heme synthesis and ALA export into the cytoplasm in cardiac myoblasts, providing evidence contrary to the commonly held hypothesis that ABCB10 may function as a heme exporter. We report that downregulation of ABCB10 impairs heme synthesis and the activities of heme-containing proteins in cardiac cells and that addition of ALA, but not overexpression of ALAS2, reverses these defects.
Methods
Methods for H9c2 cell culturing, lentiviral and adenovirial transduction, heme and total iron content determination, enzyme activity analyses, microscopy and ROS quantification, mRNA and protein level measurements, 14 
Results

ABCB10 Regulates Heme Levels in Cardiac Cells
Studies have shown that ABCB10 is required for normal hematopoiesis possibly via heme export from the mitochondria. 20, 21, 24, 26 To test this hypothesis, we measured heme levels and total mitochondrial iron content with ABCB10 modulation in H9c2 cardiac myoblasts. We effectively downregulated ABCB10 by lentiviral transduction of short hairpin RNA (shRNA) and overexpressed this protein using adenovirus, as evidenced by Western blot (Online Figure I) . Furthermore, our isolation protocol yielded highly enriched mitochondrial and cytosolic fractions (Online Figure IIA) .
Overexpression of ABCB10 had no effect on mitochondrial or total cellular heme levels in H9c2 cells ( Figure 1A and 1B). However, cellular and mitochondrial heme content was significantly reduced by ABCB10 knockdown in H9c2 cells ( Figure 1C and 1D) and in NRCM (Online Figure IIB-IID) . The reduction in heme was not caused by a decrease in nonheme mitochondrial iron levels, which were unaffected by ABCB10 downregulation (Online Figure IIE) . It is important to note that mitochondrial heme levels were reduced, not increased, by ABCB10 knockdown, in contrast to the commonly stated hypothesis that ABCB10 functions in heme export.
Consistent with a reduction in heme content, the activities of several heme-containing enzymes were decreased with ABCB10 knockdown (Figure 2A-2C ), whereas their mRNA and protein levels remained unchanged (Online Figure IIIA and IIIB). However, we observed no change in the activities or mRNA levels of heme-containing enzymes with ABCB10 overexpression ( Figure 2D -2F and Online Figure IIIC) , which is in agreement with unaltered heme content in these cells. Thus, our results suggest that ABCB10 regulates the heme biosynthetic pathway, but does not seem to be involved in heme export out of the mitochondria. 
ABCB10 Does Not Alter Levels of Heme Synthetic or Degrading Enzymes
To determine how knockdown of ABCB10 reduces heme content, we measured the levels of enzymes catalyzing each of the 8 steps in the heme biosynthesis pathway. The mRNA and protein levels of ALAS1, the rate-limiting enzyme in heme synthesis, were not altered with ABCB10 knockdown (Figure 3A and 3B; Online Figure IVA ). In addition, there was a small increase in mRNA levels of uroporphyrinogen decarboxylase and protoporphyrinogen oxidase and no difference in mRNA levels of other heme synthetic enzymes (Online Figure IVA) . Similarly, there was no change in the expression of ALAS1 and most of the other heme synthetic enzymes with ABCB10 overexpression (Online Figure IVB) . Finally, we detected no difference in the levels of heme oxygenase 1 and 2 with ABCB10 knockdown (Online Figure IVC) , suggesting that the decrease in heme content was not because of enhanced degradation. A recent study showed that ABCB10 transiently interacts with ferrochelatase, the last enzyme in the heme biosynthetic pathway. 21 Thus, we hypothesized that ABCB10 may play a role in the incorporation of iron into the PPIX ring to form heme. To test this, we assessed the effects of ABCB10 knockdown on incorporation of 55 Fe into PPIX by supplementing cells with ALA to enhance heme production and measuring radioactivity in the organic fraction containing heme, as described. 28 Consistent with our earlier observations, ABCB10 downregulation reduced total cellular porphyrin levels ( Figure 3C ), and addition of ALA completely reversed this defect ( Figure 3D ). However, incorporation of 55 Fe into the PPIX ring was unaffected by ABCB10 knockdown ( Figure 3E ), arguing against the hypothesis that ABCB10 is involved in the last steps of heme synthesis.
ABCB10 Facilitates ALA Production or Export From the Mitochondria
We next hypothesized that ABCB10 may play a role in the early mitochondrial steps of heme biosynthetic pathway, namely the production of ALA by ALAS1 or export of ALA from the mitochondria. This hypothesis predicts that addition of exogenous ALA would rescue the heme defect observed with ABCB10 knockdown. Consistently, the reduction in total cellular and mitochondrial heme levels with ABCB10 knockdown ( Figure 1C incorporation of radioactive glycine into heme that was measured in the organic phase (Online Figure IVE) .
One potential explanation for the defect in heme synthesis with ABCB10 shRNA and its reversal by the addition of exogenous ALA is a reduction in mitochondrial bioenergetic function as a result of increased ROS levels and subsequent deficiency in succinyl CoA, a necessary substrate for the synthesis of ALA and heme. To address this possibility, we supplemented cells with membrane-permeable methyl succinate 29 and measured the effects of ABCB10 knockdown on heme production. The addition of methyl succinate led to a small but significant increase in heme levels in the control cells, but failed to restore heme content in ABCB10 shRNA cells ( Figure 4F ), suggesting that the defect observed with ABCB10 knockdown is not because of succinyl CoA deficiency.
As ABCB10 knockdown is associated with a defect in hemoglobinization and differentiation of erythropoietic lineage both in vitro and in vivo, 26 we assessed the effects of ALA supplementation on these parameters in MEL cells with ABCB10 knockdown. We used small interfering RNA (siRNA) approach to knock down ABCB10 in MEL cells and achieved ≈50% reduction in its mRNA and protein levels (Online Figure VA and VB). Consistent with our hypothesis, ABCB10 knockdown reduced both heme content and differentiation of MEL cells (Online Figure VC and VE) , whereas addition of exogenous ALA reversed these defects (Online Figure VD and VE) . These findings suggest that ABCB10 also facilitates mitochondrial ALA synthesis or export in erythroid progenitor cells, and this function of ABCB10 is necessary for erythrocytic differentiation.
ALAS2 Overexpression Does Not Restore Heme Levels With ABCB10 Knockdown
Finally, to show that ABCB10 functions downstream of ALA synthesis step, we measured heme levels with simultaneous knockdown of ABCB10 and overexpression of ALAS, the mitochondrial rate-limiting enzyme that combines glycine and succinyl-CoA to form ALA. We successfully overexpressed zebrafish ALAS2 using a lentiviral vector (Online Figure VIA and VIB) , which resulted in a significant increase in total cellular heme content (Online Figure VIC) . However, we observed no increase in heme levels with zebrafish ALAS2 overexpression in cells treated with ABCB10 shRNA (Figure 4G ). Overexpression of zebrafish ALAS2 in NRCM similarly increased cellular heme levels in control shRNA group, but failed to rescue the heme defect in ABCB10 shRNA group (Online Figure VID-VIF) . These data, together with our finding that ABCB10 knockdown or overexpression does not alter the mRNA and protein levels of ALAS1, suggest that ABCB10 functions to facilitate ALA export, rather than to regulate production of ALA by ALAS1 enzyme.
ABCB10 Is Important for Cardiomyocyte's Response to Hypoxia
We recently showed that hypoxia increases heme production in the heart via upregulation of the rate-limiting enzyme, ALAS2, catalyzing mitochondrial synthesis of ALA. 30 The increased rate of ALA synthesis would require higher export capacity to efficiently deliver this intermediate into the cytosol. Consistently, mRNA and protein levels of ABCB10 were higher in H9c2 cells subjected to 48 hours of 1% O 2 than in cells grown in normoxia ( Figure 5A protein ( Figure 5A ) and abolished the hypoxia-mediated increase in heme ( Figure 5B ). These findings suggest that upregulation of ABCB10 is needed to support the increase in heme synthesis in hypoxia, and inhibition of ABCB10 upregulation is sufficient to halt heme production under hypoxic conditions. To determine whether hypoxia-driven upregulation of ABCB10 bears physiological consequences, we assessed ROS levels and cell death in cardiac cells subjected to 48 hours of hypoxia, followed by 30 minutes of reoxygenation with and without knockdown of ABCB10. Failure to upregulate ABCB10 in hypoxia as a result of siRNA treatment was associated with increased oxidative stress, as determined by the superoxide-sensitive dye MitoSox ( Figure 5C ). The accumulation of MitoSox in the mitochondria was not caused by changes in mitochondrial membrane potential, as tetramethylrhodamine, ethyl ester staining did not differ between the groups (Online Figure VIG) . Furthermore, cell death was significantly increased in hypoxic cells in which ABCB10 upregulation was suppressed ( Figure 5D ) and further augmented by addition of hydrogen peroxide as a source of oxidative stress ( Figure 5E ). Thus, in contrast to forced overexpression of ABCB10 in normoxia which does not alter heme synthesis, physiological induction of ABCB10 in hypoxia is necessary to support increased rates of heme synthesis, and failure to maintain adequate ABCB10 levels compromises cell survival.
ABCB10 Levels Are Increased in Cardiomyopathy
To determine whether ABCB10 expression is altered in ischemic heart disease, we measured the levels of this protein in the hearts of mice subjected to MI. We observed a progressive increase in ABCB10 expression in the heart after MI compared with sham-operated controls, with >2-fold elevation in ABCB10 protein levels 1 month after MI ( Figure 6A ). The increase in ABCB10 protein was associated with higher cellular and mitochondrial heme levels in mouse hearts 1 month after MI ( Figure 6B and 6C) . Furthermore, there was also an increase in ABCB10 content in the explanted hearts from human patients with ischemic cardiomyopathy compared with the nonmyopathic human hearts (Figure 6D ), which was paralleled by increased heme levels in myopathic hearts ( Figure 6E) . Finally, to determine whether ABCB10 has an effect on cardiomyocyte physiology, we assessed Ca 2+ handling in NRCM with ABCB10 knockdown. In the absence of electric pacing, fewer cells in the ABCB10 siRNA group were beating spontaneously compared with the control group (17/27 versus 9/24 spontaneously beating/total cell count for control and ABCB10 siRNA, respectively). Analysis of Ca 2+ transients revealed no difference in the magnitude of transient (F/F 0 ) and rise time, but a significant prolongation of the decay time ( Figure 6F-6H) , indicative of impaired Ca 2+ removal from the cytoplasm after systolic influx. Consistent with a calcium removal defect, we . ATP-binding cassette (ABC) B10 is upregulated in the ischemic heart and modulates Ca 2+ transients. A, ABCB10 protein levels in sham-operated mice and mice subjected to myocardial infarction (MI) injury 1 week and 1 month after the surgery. Densitometric analysis is presented below the Western blot (n=3-4). Total cellular (B) and mitochondrial (C) heme levels in mouse hearts 1 month after MI or sham operation (n=3). D, ABCB10 protein levels in explanted human hearts with ischemic cardiomyopathy or in noncardiomyopathic control human hearts. Densitometric analysis is shown on the right. E, Heme levels in myopathic and nonmyopathic human hearts (n=10). Analysis of Ca 2+ transients in neonatal rat cardiomyocytes with ABCB10 and control small interfering RNA (siRNA): representative images (F), F/F 0 as a measure of transient magnitude (n=10-11 cells from 3 coverslips; G), and rise and decay times (n=15 cells from 4 coverslips; H). Data are presented as mean±SEM. *P<0.05 vs control. ICM indicates ischemic cardiomyopathy; and NM, nonmyopathic.
observed a significant reduction in protein levels of sodiumcalcium exchanger in NRCM treated with ABCB10 siRNA, compared with control (Online Figure VII) .
In summary, we showed that ABCB10 facilitates ALA export from the mitochondria into the cytosol and is required for heme synthesis. ABCB10 is positively regulated by hypoxia, and failure to increase the levels of this protein results in increased oxidative stress and loss of cell viability after hypoxia-reoxygenation injury. Finally, low ABCB10 levels are associated with slower Ca 2+ removal from the cell, and upregulation of ABCB10 in ischemic myocardium may help to protect cardiac function.
Discussion
The production of heme requires efficient shuttling of synthetic intermediates between mitochondrial and cytosolic compartments, but the transporters mediating these events are not known. 6, 31 In this report, we show for the first time that ABCB10 plays a role in early mitochondrial steps of heme synthesis, likely by facilitating ALA export out of the mitochondria, and is important for maintenance of cellular heme homeostasis in cardiac cells. Knockdown of ABCB10 in cardiac myoblasts reduces heme levels and the activities of hemecontaining proteins, whereas addition of exogenous ALA completely reverses these defects. However, increased production of ALA in the mitochondria by overexpression of the rate-limiting enzyme ALAS2 or supplementation with methyl succinate, a precursor of succinyl-CoA, fails to restore heme levels. These results suggest that ABCB10 may be involved in ALA export out of the mitochondria (Figure 7 ).
Our results demonstrate that ABCB10 knockdown reduces heme synthesis in 3 distinct cell lines, nonerythropoietic H9c2, NRCM, and erythropoietic MEL cells, providing first evidence that hemoglobinization defect observed in ABCB10 knockout mice may be because of reduced cytosolic ALA availability and impaired heme synthesis. However, the exact function of ABCB10 in hematopoiesis and the ability of ALA supplementation to reverse embryonic lethality of ABCB10 knockout mice warrant in-depth investigation. In addition, the finding of elevated heme content in mouse MI hearts indicates a novel role for ABCB10 and heme in cardiac pathology. Given that heme synthesis pathway is stimulated by hypoxia, inability to upregulate ABCB10 and provide adequate export capacity for ALA would result in ALA trapping inside the mitochondria. Because ALA is a prooxidant molecule, 32 increased cell death after hypoxia-reoxygenation injury may be secondary to the oxidative stress caused by ALA accumulation inside the mitochondria.
Our studies show that ABCB10 is needed for the cytosolic steps of heme synthesis, localizing ABCB10 function to the first 2 mitochondrial steps of the pathway: ALA production or export. The first possibility is less likely, given that ALAS1 mRNA and protein levels are unchanged with ABCB10 knockdown. Furthermore, overexpression of zebrafish ALAS2, whose sequence and regulation are distinct from that of cardiac-specific ALAS1 isoform, fails to rescue the defect in heme observed with ABCB10 knockdown. However, we cannot exclude the possibility of a primary defect in mitochondrial function, mediated by oxidative stress or other factors, which would impede ALA synthesis by inhibiting the activity of ALAS1/2 enzymes as reported previously. 33 Furthermore, although our results suggest that ABCB10 may facilitate ALA export out of the mitochondria, they do not establish ABCB10 as the actual ALA exporter. Although Graf et al 22 concluded that ABCB10 exists exclusively in the form of homodimers and higher-order homo-oligomeric complexes, the possibility still exists that ABCB10 transiently/ noncovalently interacts with yet another transporter that functions to export ALA. Recent reports of interactions among ABCB10, Mfrn1, and ferrochelatase, 21, 25 as well as ferrochelatase and ABCB7, 16 highlight the complexity of protein-protein interactions occurring at the inner mitochondrial membrane. Finally, the direct measurement of ALA export out of the isolated mitochondria could not be performed using an earlier-established method for measurement of mitochondrial export activity 19 because radioactive labeling of ALA precursors (succinyl CoA and glycine) will result in their incorporation into a variety of other cellular molecules.
ABCB10 knockout mice die in utero and ABCB10 −/− erythroid cells fail to differentiate as a result of a defect in hemoglobinization and ROS-mediated increase in apoptosis. 26 Furthermore, ABCB10 heterozygous mice display increased susceptibility to ischemia-reperfusion injury of the heart because of an acute increase in oxidative stress triggered by ischemia-reperfusion, 27 although the source of ROS has not been identified yet. We also show that knockdown of ABCB10 in cardiac myoblasts leads to increased ROS production and is associated with reduced activities of heme-containing antioxidant enzymes, peroxidases and catalases. Thus, it is tempting to speculate that the potential mechanism for the increase in ROS observed with ABCB10 deletion/ knockdown may be through a decrease in the antioxidant capacity of the cells caused by reduced availability of heme, although mitochondrial accumulation of prooxidant ALA may contribute to and further exacerbate the damage. In addition to increases in oxidative stress and cell death, we show that ABCB10 knockdown impairs Ca 2+ handling by prolonging transient decay time. Although the exact mechanism for this finding is yet to be elucidated, we show that sodium-calcium exchanger protein levels are reduced by ABCB10 knockdown, consistent with previous findings of sodium-calcium exchanger being sensitive to oxidative stress. 34, 35 Furthermore, sarcoendoplasmic reticulum Ca 2+ ATPase 2 is thought to play an important role in Ca 2+ removal during the diastolic phase. Sarcoendoplasmic reticulum Ca 2+ ATPase 2 is exquisitely sensitive to oxidative damage, undergoing multiple posttranslational modifications, including oxidation and sulfonylation of cystines, which impair its activity and cause prolongation of decay phase of the transient. 36, 37 Interestingly, Liesa et al 27 found sarcoendoplasmic reticulum Ca 2+ ATPase 2 activity to be significantly reduced in the hearts of ABCB10 heterozygous mice after ischemia-reperfusion injury, which is supportive of our data. Disruption of Ca 2+ transients by ABCB10 knockdown suggests that changes in the levels of this protein may indirectly influence cardiac contractility.
Overexpression of ABCB10 in cardiac myoblasts did not increase heme content, consistent with previous reports and with the rate-limiting role of ALAS1 in heme synthesis, 5 whereas knockdown of ABCB10 significantly reduced heme levels. This raises a question about physiological significance of ABCB10 upregulation in the mouse MI model and in human hearts with ischemic cardiomyopathy. Important to note, however, that in the former set of experiments ABCB10 levels were increased artificially through forced adenoviral overexpression. As shown in Online Figure IVB , ABCB10 overexpression did not alter the levels of heme synthetic enzymes. Although ALA export capacity was increased in this setting, the levels of ALAS1, the enzyme required for ALA production in the mitochondria, remained unchanged. Thus, one would not expect heme levels to be altered by forced overexpression of ABCB10. However, upregulation of ABCB10 in hypoxia and ischemic hearts parallels overall induction of heme synthetic pathway and heightened requirements for ALA export. We reported earlier that heme synthesis is increased in ischemic human failing hearts and in cardiac cells subjected to hypoxia through upregulation of ALAS2. 30 In this setting, upregulation of ABCB10 is required to support increased demand for ALA transport. Consistently, we show that suppression of ABCB10 upregulation by hypoxia is sufficient to repress heme production and leads to increased cell death. Our conclusions are supported by Shirihai et al, 20 who also show that forced overexpression of ABCB10 does not increase hemoglobinization of undifferentiated MEL cells in which heme synthesis pathway is inactive. However, ABCB10 overexpression, together with induction of differentiation (which is a strong stimulus for increased heme production), promotes hemoglobinization. 20 Thus, overexpression of ABCB10 facilitates heme synthesis when other steps in heme synthesis (particularly those needed for ALA production) are also active.
A recent study showed that ABCB10 binds to and stabilizes Mfrn1 in MEL cells, 25 although this interaction has not yet been confirmed in the heart. Thus, ABCB10 knockdown is expected to reduce mitochondrial iron levels through destabilization of Mfrn1, which we failed to observe in our studies. Mfrn1 is expressed in low levels in the heart, whereas Mfrn2 is the predominant isoform responsible for the majority of iron imported into the mitochondria. [7] [8] [9] Given that ABCB10 does not regulate expression or stability of Mfrn2, 25 reduction in Mfrn1 with ABCB10 loss is unlikely to alter mitochondrial iron uptake in cardiac myoblasts. Finally, a weak interaction between ABCB10 and ferrochelatase has been reported in hematopoietic cells 21 but has not been studied in other cell types. We show that ABCB10 knockdown in cardiac cells does not affect ferrochelatase levels or activity, as we observed no change in iron incorporation into PPIX. Consistent with our findings, Chen et al 25 also report no difference in iron incorporation into PPIX, with coexpression of Mfrn1 and ABCB10 in MEL cells. Thus, the relevance of ferrochelatase-ABCB10 interaction remains to be determined.
In summary, we have shown that knockdown of ABCB10 causes a reduction in cytosolic and mitochondrial heme levels, possibly as a result of reduced cytosolic ALA levels. Importantly, our findings are contrary to the commonly held hypothesis that ABCB10 functions in mitochondrial heme export, which would predict increased mitochondrial and reduced cytosolic heme levels because of mitochondrial trapping of heme with ABCB10 knockdown.
